ZURICH: Roche has won the U.S. Food and Drug Administration's breakthrough therapy tag for its drug Gazyva in lupus nephritis, the Swiss drugmaker said on Wednesday, boosting its efforts to recycle the 2013-approved lymphoma medicine for new indications. There are no FDA-approved medicines for lupus nephritis, a life-threatening symptom of the autoimmune disease lupus in which the kidneys grow inflamed. Roche has heralded Gazyva's potential in the new disease area in helping turn the drug that had sales of 390 million Swiss francs ($392.59 million) last year into a commercial success. ($1 = 0.9934 Swiss francs)
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!